Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/354911


Analytical Tool - Leukemia Therapeutics & Competitive Insights


Description: "Analytical Tool - Leukemia Therapeutics & Competitive Insights" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in leukemia R&D and business development. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are two products already appreciated by many of our customers - Leukemia - A Therapeutic & Competitive Insight and Leukemia Drug Pipeline Update 2007-.

The Package Includes:

A progress analysis on current and emerging drugs
Information on most companies active in leukemia R&D
Information on key industry related leukemia projects
Data from most important clinical trials
Information on early developmental stage projects
Possibility of performing advanced searches suited to your individual needs
This Tool will Assist You in:

Tracking cutting edge companies, therapies and new technologies
Rapid identification of partners & competitors
Laying down a comprehensive framework for further analysis of the field
Producing presentations surrounding the development of leukemia therapeutics
Identifying emerging leukemia products & key areas of pharmaceutical R&D
-BioSeekers CD-ROM searchable database reflects the most recent advances in the field of leukemia development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker Group CD-ROM searchable databases is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker Group’s CD-ROM searchable databases give better overview and specific search capabilities.


Contents: 1 Executive Summary

2 Cancer Highlights

3 Methodology

4 List of Contents

4.1 List of Boxes
4.2 List of Tables

5 Introduction

5.1 Disease Definitions
5.1.1 The Lymphoid Malignancies
5.1.2 The Myeloid Malignancies
5.2 Etiology & Pathophysiology
5.2.1 The Lymphoid Malignancies
5.2.2 The Myeloid Malignancies.
5.3 Epidemiology
5.4 Prognosis
5.4.1 The Lymphoid Malignancies
5.4.2 The Myeloid Malignancies

6 Current Treatment Strategies

6.1 The Lymphoid Malignancies
6.2 The Myeloid Malignancies

7 Progress in Current Treatment Strategies

7.1 The Lymphoid Malignancies
7.2 The Myeloid Malignancies

8 Key Therapeutic Strategies for Future Therapies

8.1 Therapeutic type, Targets & Mechanisms

9 Competitive Landscape in Drug Development: The Late Stage Pipeline

9.1 The Lymphoid Malignancies
9.2 The Myeloid Malignancies

10 Current Drug Development: The Early Stage Pipeline

10.1 The Myeloid Malignancies
10.2 The Lymphoid Malignancies

11 Disclaimer

11.1 Liability
11.2 Completeness

12 Appendix: Drugs Approved for the Treatment of Leukemia: A
Historical Perspective

13 Drug Index
39H

14 Company Index

4.1 List of Boxes

40HBox 1: Major treatment regimes
41HBox 2: CLL staging system
42HBox 3: Updated REAL/WHO Classification for B-Cell Neoplasms
43HBox 4: Quick Facts - Clofarabine
4HBox 5: Quick Facts - Alemtuzumab
45HBox 6: Quick Facts - Gemtuzumab
46HBox 7: Quick Facts - Imatinib
47HBox 8: Quick Facts - Rituximab
48HBox 9: Quick Facts - Genasense
49HBox 10: Quick Facts - Flavopiridol
50HBox 11: Quick Facts - Atra
51HBox 12: Quick Facts - Gvax
52HBox 13: Quick Facts - Zarnestra
53HBox 14: Quick Facts - BAY 43-9006
54HBox 15: Quick Facts - Ceplene
5HBox 16: Quick Facts - Valspodar
56HBox 17: Quick Facts - CEP-701
57HBox 18: Quick Facts - PKC412
58HBox 19: Quick Facts - SU5416
59HBox 20: Quick Facts - PTK787
60HBox 21: Quick Facts - Cloretazine
61HBox 22: Company statement on progress
62HBox 23: Quick Facts - Troxacitabine
63HBox 24: Quick Facts - FK228
64HBox 25: Quick Facts - Decitabine
65HBox 26: Quick Facts - VELCADE
6HBox 27: Velcade sales 2005
67HBox 28: Quick Facts - AG-858
68HBox 29: Quick Facts - Avastin
69HBox 30: Quick Facts - OSI-461
70HBox 31: Quick Facts - Xcytrin
71HBox 32: Quick Facts - AP23573

4.2 List of Tables

72H Table 1: ALL Classification
73HTable 2: Latest Approved Drugs for the Treatment of Leukemia
74HTable 3: Kinase Inhibitors in Development for the Treatment of Leukemia
75HTable 4: Near Term Progress Rituximab
76HTable 5: Near Term Progress Oblimersen
7HTable 6: Near Term Progress Alvocidib
78HTable 7: Near Term Progress ATRA
79HTable 8: Near Term Progress GVAX
Table 9: Near Tearm Progress HuM195
Table 10: Near Term Progress Zarnestra
Table 11: Near Term Progress Sorafenib
Table 12: Near Term Progress Valspodar
Table 13: Summary of Current Late Stage Pipeline
Table 14: Near Term Progress CEP-701
Table 15: Near Term Progress PKC412
Table 16: Near Term Progress SU5416
Table 17: Near Term Progress PTK787
Table 18: Near Term Progress VNP40101M
Table 19: Near Term Progress Troxacitabine
Table 20: Near Term Progress Decitabine
Table 21 Near Term Progress Bortezomib
Table 22 Near Term Progress AG-858
Table 23: Near Term Progress bevacizumab
Table 24: Near Term Progress OSI-461
Table 25: Near Term Progress Xcytrin
Table 26: Near Term Progress AP23573
Table 27: Summary of Current Early Stage Pipeline




Ordering: Order Online - visit http://www.researchandmarkets.com/reports/354911

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 22/11/2008 12:56:10
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com


Order information

Please verify that the product information is correct and select the format you require.

Product Name:
Analytical Tool - Leukemia Therapeutics & Competitive Insights
Web Address:
http://www.researchandmarkets.com/reports/354911
Office Code:
OCIEGLKNMPW

Report formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €3,100.00
Electronic (PDF) - Site License €6,200.00
Electronic (PDF) - Enterprisewide €9,300.00




Contact information

Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Research and Markets Page 2 of 2
Printed 22/11/2008 12:56:10

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder Name:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.


If you have a Marketing Code please enter it below:

Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp



Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World